Tumor necrosis factor ligand superfamily member 12-member 13 fusion protein (TNFSF12-TNFSF13)

TNFSF12-TNFSF13 is a **fusion protein** formed by intergenic splicing of TWEAK (TNFSF12) and APRIL (TNFSF13) genes, resulting in a membrane-anchored cytokine (*TWE-PRIL*) that presents APRIL's receptor-binding domain at the cell surface[1][2][4][9]. It is expressed in activated T lymphocytes and monocytes, and stimulates proliferation and survival of T and B cell lines by engaging APRIL’s typical receptors (BCMA, TACI, and possibly others)[4]. Its production reflects a complex regulation and structural diversity within the TNF ligand superfamily. The precise physiological and pathological roles are still being elucidated, but it shares functional similarities with APRIL (e.g., tumor promotion, immune modulation) and may have unique properties due to membrane anchoring[2][4][5]. This molecule is of translational interest as a cytokine/receptor ligand with potential roles in cancer and immune diseases, but there is currently limited information on drugs or clinical targeting specifically for TWE-PRIL.

Other names

TWE-PRILTNFSF12-TNFSF13 proteinTumor necrosis factor (ligand) superfamily, member 12-member 13TWEAK-APRIL fusion protein

Antibody-mediated cytokine neutralization (theoretical, based on its APRIL domain); Modulation of lymphocyte proliferation and survival, via ligand-receptor interactions (primarily with BCMA, TACI, and possibly others for APRIL domain)